Ocular Hypertension clinical trials at University of California Health
3 in progress, 2 open to eligible people
Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
open to eligible people ages 18 years and up
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
at UCSF
Clarifying the Optimal Application of SLT Therapy Trial
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
at UC Davis UCLA UCSF
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Sorry, accepting new patients by invitation only
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
at UCSD
Our lead scientists for Ocular Hypertension research studies include James Brandt, MD Ying Han, MD Julius Oatts, MD.